Evidence map›Paper›PMID 37364047›Full record

ArticleDiabetes2023

Deletion of Carboxypeptidase E in β-Cells Disrupts Proinsulin Processing but Does Not Lead to Spontaneous Development of Diabetes in Mice.

Yi-Chun Chen, Austin J Taylor, James M Fulcher, Adam C Swensen, Xiao-Qing Dai, Mitsuhiro Komba, Kenzie L C Wrightson, Kenny Fok, Annette E Patterson, Ramon I Klein Geltink and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Diabetes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Yi-Chun ChenDepartment of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0003-4328-0383
Austin J TaylorBC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.ORCID 0000-0001-8167-1209
James M FulcherIntegrative Omics, Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA.ORCID 0000-0001-9033-3623
Adam C SwensenIntegrative Omics, Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA.ORCID 0000-0001-8135-1766
Xiao-Qing DaiDepartment of Pharmacology, University of Alberta, Edmonton, Alberta, Canada.
Mitsuhiro KombaDepartment of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0001-7485-1746
Kenzie L C WrightsonBC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.ORCID 0000-0001-8914-530X
Kenny FokBC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
Annette E PattersonBC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
Ramon I Klein GeltinkBC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.ORCID 0000-0003-4610-3059
Patrick E MacDonaldDepartment of Pharmacology, University of Alberta, Edmonton, Alberta, Canada.ORCID 0000-0002-5439-6288
Wei-Jun QianIntegrative Omics, Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA.ORCID 0000-0002-5393-2827
C Bruce VerchereDepartment of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0002-9262-0586
University of British Columbia · CAPacific Northwest National Laboratory · USBC Children's Hospital · CAUniversity of Alberta · CA

Funding

Pathways and Regulators Driving Progressive Islet Cell Dysfunction in Type 1 DiabetesR01DK122160 · NIDDK · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI ROHIT N. KULKARNI, CLAYTON E MATHEWS · 2019 to 2026
$3.7M
Multiplex Mass Spectrometric Protein Assays for Precise Monitoring of the Pathophysiology of ObesityU01DK124020 · NIDDK · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI QIAN, WEI-JUN · 2019 to 2022
$3.3M
NIDDK NIH HHS R01 DK122160NIDDK NIH HHS U01 DK124020NIH HHS R01DK122160
6 · The paper itself

Abstract

Carboxypeptidase E (CPE) facilitates the conversion of prohormones into mature hormones and is highly expressed in multiple neuroendocrine tissues. Carriers of CPE mutations have elevated plasma proinsulin and develop severe obesity and hyperglycemia. We aimed to determine whether loss of Cpe in pancreatic β-cells disrupts proinsulin processing and accelerates development of diabetes and obesity in mice. Pancreatic β-cell-specific Cpe knockout mice (βCpeKO; Cpefl/fl x Ins1Cre/+) lack mature insulin granules and have elevated proinsulin in plasma; however, glucose-and KCl-stimulated insulin secretion in βCpeKO islets remained intact. High-fat diet-fed βCpeKO mice showed weight gain and glucose tolerance comparable with those of Wt littermates. Notably, β-cell area was increased in chow-fed βCpeKO mice and β-cell replication was elevated in βCpeKO islets. Transcriptomic analysis of βCpeKO β-cells revealed elevated glycolysis and Hif1α-target gene expression. On high glucose challenge, β-cells from βCpeKO mice showed reduced mitochondrial membrane potential, increased reactive oxygen species, reduced MafA, and elevated Aldh1a3 transcript levels. Following multiple low-dose streptozotocin injections, βCpeKO mice had accelerated development of hyperglycemia with reduced β-cell insulin and Glut2 expression. These findings suggest that Cpe and proper proinsulin processing are critical in maintaining β-cell function during the development of hyperglycemia. ARTICLE HIGHLIGHTS: Carboxypeptidase E (Cpe) is an enzyme that removes the carboxy-terminal arginine and lysine residues from peptide precursors. Mutations in CPE lead to obesity and type 2 diabetes in humans, and whole-body Cpe knockout or mutant mice are obese and hyperglycemic and fail to convert proinsulin to insulin. We show that β-cell-specific Cpe deletion in mice (βCpeKO) does not lead to the development of obesity or hyperglycemia, even after prolonged high-fat diet treatment. However, β-cell proliferation rate and β-cell area are increased, and the development of hyperglycemia induced by multiple low-dose streptozotocin injections is accelerated in βCpeKO mice.

Indexed as

Carboxypeptidase HDiabetes Mellitus, Type 2HyperglycemiaInsulin-Secreting CellsIslets of LangerhansAnimalsGlucoseInsulinMiceMice, KnockoutObesityProinsulinStreptozocinCarboxypeptidase HGlucoseInsulinProinsulinStreptozocin

Identifiers

PMID37364047
PMCPMC10450824
OpenAlexW4382048753

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.